Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

ALK-positive NSCLC Clinical Trial

Official title:
Real-world Study of Non-small Cell Lung Cancer Treatment With ALK-tyrosine Kinase Inhibitors (ALK TKI) in Sweden: Drug Sequencing, Treatment Duration and Overall Survival - A Retrospective Study Using Swedish Register Data

Status Completed

Clinical Trial Summary

This study aims to explore for the first time how the different ALK TKIs have been sequenced in real-world clinical practice and with which outcomes for Swedish lung cancer patients

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

ALK-positive NSCLC

Clinical Trial Details

NCT number	NCT04647110
Study type	Observational
Source	Pfizer
Contact
Status	Completed
Phase
Start date	December 14, 2020
Completion date	March 15, 2021

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05482087` - A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC	Phase 2
Active, not recruiting	`NCT02393625` - Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer	Phase 1
Recruiting	`NCT03804541` - The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human	Phase 1
Recruiting	`NCT04009317` - Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)	Phase 3
Recruiting	`NCT04056572` - Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib	Phase 2